<DOC>
	<DOCNO>NCT00303836</DOCNO>
	<brief_summary>This randomized phase II trial study well give vaccine therapy without interleukin-2 chemotherapy autologous white blood cell infusion work treat patient metastatic melanoma . Vaccines make peptide may help body build effective immune response kill tumor cell . Giving vaccine therapy interleukin-2 , chemotherapy , autologous white blood cell infusion may effective treatment metastatic melanoma .</brief_summary>
	<brief_title>Vaccine Therapy With Without Interleukin-2 After Chemotherapy Autologous White Blood Cell Infusion Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine ability gp100 MART-1 peptide vaccine without high-dose interleukin-2 ( IL-2 ) , administer nonmyeloablative , lymphodepleting preparative regimen reinfusion autologous CD25+ T-regulatory-depleted lymphocyte , mediate tumor regression patient metastatic melanoma . SECONDARY OBJECTIVES : I . Determine generation antitumor lymphocyte rate repopulation CD25+ T-regulatory cell patient treat regimen . II . Determine toxicity treatment regimen . OUTLINE : This randomize study . Patients randomize 1 2 treatment arm . ARM I : Patients undergo apheresis in-vitro depletion T-regulatory cell . Patients receive nonmyeloablative , lymphocyte-depleting preparative regimen comprise cyclophosphamide IV 1 hour day -8 -7 fludarabine IV 15-30 minute day -6 -2 follow autologous T-regulatory-depleted lymphocyte IV 20-30 minute day 0 . Patients receive vaccination gp100:209-217 ( 210M ) MART-1:27-35 peptide emulsify Montanide ISA-51 subcutaneously ( SC ) day 0-3 , 20-23 , 41-44 , 62-65 . Patients also receive filgrastim ( G-CSF ) SC begin day 1 continue blood count recover . ARM II : Patients receive treatment arm I . Patients also receive high-dose IL-2 IV 15 minute every 8 hour day 0-4 , begin lymphocyte infusion . IL-2 treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 1-3 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Diagnosis metastatic melanoma No tumor reactive cell available cell transfer therapy Measurable disease Previously treat interleukin2 ( IL2 ) meet 1 follow criterion : No response ( progressive disease ) Recurrent disease HLA*0201 positive ECOG performance status 0 1 Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin &gt; 8.0 g/dL ALT AST &lt; 3 time upper limit normal Bilirubin ≤ 2.0 mg/dL ( &lt; 3.0 mg/dL Gilbert 's disease present ) Creatinine ≤ 2.0 mg/dL Life expectancy ≥ 3 month Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 month receive preparative regimen No active systemic infection , coagulation disorder , major medical illness cardiovascular , respiratory , immune system , evidence positive stress thallium comparable test , myocardial infarction , cardiac arrhythmia , obstructive restrictive pulmonary disease No autoimmune disease ( e.g. , autoimmune colitis Crohn 's disease ) primary immunodeficiency disease No HIV positivity No hepatitis B C virus positivity No EpsteinBarr virus negativity Eligible receive highdose IL2 , evidence following : Patients ≥ 50 year age must normal cardiac stress test ( e.g. , stress thallium , stress MUGA , dobutamine echocardiogram , stress test ) AND LVEF ≥ 45 % Patients history EKG abnormality , symptom cardiac ischemia , arrhythmias must normal cardiac stress test AND LVEF ≥ 45 % Patients prolonged history cigarette smoking symptom respiratory dysfunction must normal pulmonary function test , evidence FEV 1 ≥ 60 % predict At least 4 week since prior systemic therapy At least 6 week since prior nitrosourea therapy No concurrent systemic steroid therapy Recovered immune competence prior chemotherapy radiotherapy No prior gp100:209217 MART1:2735 peptide vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>